Regulus Therapeutics (RGLS) News Today $7.95 +0.08 (+1.02%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RGLS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Regulus Therapeutics (NASDAQ:RGLS) Earns Sell Rating from Analysts at StockNews.comStockNews.com assumed coverage on shares of Regulus Therapeutics in a research note on Sunday. They issued a "sell" rating for the company.May 20 at 3:16 AM | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.comMay 19 at 2:45 AM | americanbankingnews.comOctagon Capital Advisors LP Acquires 585,101 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)Octagon Capital Advisors LP grew its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,848,802 shares of the biopharmaMay 15, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.comStockNews.com started coverage on shares of Regulus Therapeutics in a report on Saturday. They set a "sell" rating for the company.May 12, 2025 | marketbeat.comRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 9, 2025 | finanznachrichten.deRegulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 8, 2025 | prnewswire.comWhat is Leerink Partnrs' Estimate for RGLS Q1 Earnings?Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Regulus Therapeutics in a research note issued on Wednesday, April 30th. Leerink Partnrs analyst J. Schwartz anticipates that the biopharmaceutical company will eMay 6, 2025 | marketbeat.comJPMorgan Chase & Co. Purchases 111,485 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)JPMorgan Chase & Co. grew its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 141.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190,457 shares of the biopharmaceutMay 5, 2025 | marketbeat.comREGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLSMay 4, 2025 | businesswire.comNovartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion DealMay 4, 2025 | gurufocus.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Sees Large Decline in Short InterestRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 2,110,000 shares, a decrease of 20.7% from the March 31st total of 2,660,000 shares. Approximately 4.0% of the shares of the company are sold short. Based on an average daily volume of 1,210,000 shares, the days-to-cover ratio is currently 1.7 days.May 4, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Lowered to "Hold" Rating by Wells Fargo & CompanyWells Fargo & Company cut shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday.May 4, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Downgraded to "Hold" Rating by Leerink PartnrsLeerink Partnrs lowered Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday.May 4, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by RA Capital Management L.P.RA Capital Management L.P. trimmed its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 56.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 336,843 shares of the biopharmaceuticMay 3, 2025 | marketbeat.comRegulus Therapeutics (RGLS) Projected to Post Earnings on ThursdayRegulus Therapeutics (NASDAQ:RGLS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-regulus-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comWells Fargo Downgrades Regulus Therapeutics (RGLS)May 2, 2025 | msn.comNovartis to buy Regulus Therapeutics for as much as $1.7 billionMay 2, 2025 | latimes.comRegulus Therapeutics (NASDAQ:RGLS) Shares Pass Above 200-Day Moving Average - Here's What HappenedRegulus Therapeutics (NASDAQ:RGLS) Shares Pass Above 200-Day Moving Average - Here's WhyMay 2, 2025 | marketbeat.comJones Trading Downgrades Regulus Therapeutics (RGLS)May 1, 2025 | msn.comNovartis Acquires Regulus Therapeutics for $800 MillionMay 1, 2025 | gurufocus.comNovartis to Acquire Regulus Therapeutics in $1.7 Billion DealMay 1, 2025 | gurufocus.comRegulus Therapeutics Acquisition By Novartis Due To Key Farabursen AdvancementsApril 30, 2025 | seekingalpha.comRegulus Therapeutics Inc.: Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AGApril 30, 2025 | finanznachrichten.deRegulus Therapeutics stock soars on acquisition deal with NovartisApril 30, 2025 | za.investing.comNovartis to buy kidney disease drug maker Regulus in up to $1.7 billion dealApril 30, 2025 | msn.comRegulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From NovartisApril 30, 2025 | msn.comRegulus Therapeutics Acquisition By Novartis Due To Key Farabursen AdvancementsApril 30, 2025 | seekingalpha.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLSApril 30, 2025 | prnewswire.comCrude Oil Falls Over 3%; Regulus Therapeutics Shares Spike HigherApril 30, 2025 | benzinga.comNovartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 MillionApril 30, 2025 | benzinga.comRGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics ...April 30, 2025 | gurufocus.comNovartis (NVS) to Acquire Regulus Therapeutics in $0.8B Deal | NVS Stock NewsApril 30, 2025 | gurufocus.comNovartis (NVS) to Acquire Regulus Therapeutics for $0.8BApril 30, 2025 | gurufocus.comShareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. ...April 30, 2025 | gurufocus.comShareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public ShareholdersApril 30, 2025 | businesswire.comNovartis to buy Regulus Therapeutics for up to $1.7 billionApril 30, 2025 | reuters.comNovartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failureApril 30, 2025 | globenewswire.comRegulus Therapeutics Enters into Agreement to be Acquired by Novartis AGApril 30, 2025 | prnewswire.comRegulus Therapeutics (RGLS): A Promising Penny Stock for 2025April 28, 2025 | gurufocus.comRegulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200 Day Moving Average - Time to Sell?Regulus Therapeutics (NASDAQ:RGLS) Stock Crosses Above 200 Day Moving Average - Should You Sell?April 24, 2025 | marketbeat.comShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 30.4%Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,660,000 shares, a growth of 30.4% from the March 15th total of 2,040,000 shares. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is presently 2.4 days. Approximately 5.0% of the shares of the company are sold short.April 21, 2025 | marketbeat.comIs Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | insidermonkey.comIs Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comRegulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?Regulus Therapeutics (NASDAQ:RGLS) Stock Passes Above Two Hundred Day Moving Average - Here's What HappenedApril 14, 2025 | marketbeat.comRegulus Therapeutics Inc (RGLS)April 10, 2025 | uk.investing.comRegulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?Regulus Therapeutics (NASDAQ:RGLS) Stock Passes Above 200 Day Moving Average - Time to Sell?April 5, 2025 | marketbeat.comRegulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech SummitApril 2, 2025 | prnewswire.comRegulus Therapeutics Leads The Charge Among 3 Promising Penny StocksMarch 31, 2025 | uk.finance.yahoo.comRegulus upgraded to Overweight from Equal Weight at Wells FargoMarch 29, 2025 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)March 29, 2025 | markets.businessinsider.com Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address RGLS Media Mentions By Week RGLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGLS News Sentiment▼0.900.65▲Average Medical News Sentiment RGLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGLS Articles This Week▼32▲RGLS Articles Average Week Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BioCryst Pharmaceuticals News Ligand Pharmaceuticals News Amicus Therapeutics News Celldex Therapeutics News MannKind News Novavax News Dynavax Technologies News Innoviva News OPKO Health News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGLS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGLS Stock Free RGLS Stock Alerts